NextCure shareholders approve amended 2019 incentive plan adding 80,000 shares

• NextCure held its annual shareholder meeting on June 18, 2026.
• Shareholders adopted an amended and restated 2019 Omnibus Incentive Plan, authorizing 80,000 additional shares for issuance under the plan.
• The plan’s evergreen feature was revised so the annual increase is based on fully diluted outstanding shares, including outstanding prefunded warrants.
• Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-077546), on June 25, 2026, and is solely responsible for the information contained therein.